Array Technologies looks deeply undervalued after a 91% drop, with strong FCF yield and solar tailwinds. See why ARRY stock ...

Fory 1.7.0 release also expands Swift platform support and supports incremental JSON stream decoding for top-level arrays and ...

Pennsylvania’s Solar for Schools Program is funding solar projects at 84 schools, including Steelton-Highspire, cutting energy costs and supporting clean energy.

Casimir won a Small Business Technology Transfer Program contract to use its quantum technology to develop a solid-state generator for the Air Force. The startup submitted the proposal in partnership ...

Indian-origin Nasa astronaut Anil Menon is set to conduct his first spacewalk outside the International Space Station (ISS) on Thursday, joining veteran astronaut Jessica Meir for a seven-hour ...

OPPD opened its newest generation facilities with a ribbon cutting ceremony as well as a ground breaking for a third one to be built The Omaha Public Power District announced Wednesday that it has ...

Matthew Rodriguez is a digital producer for CBS Los Angeles. He's previously reported for local outlets like the Argonaut and Pasadena Weekly. Matt typically covers breaking news and crime. Julie ...

As more and more data centers are proposed throughout the region and the state, the issues critics bring to the table are becoming fairly familiar — the amount of water used to cool the servers, air ...

Has Elon Musk given up on Tesla’s Master Plans, on the electrified economy, on solar power as we know it? From the SpaceX IPO filing released this week, it sure seems like it. A recap for those not ...

Pragmata's map is bigger and more full of secrets than you might expect from what initially seems like a series of hallways. Nooks filled with danger and crannies hiding treasure abound, but it's easy ...

A firm called Generate Biomedicines is making waves in pharma as a brand-new IPO re-inventing drug discovery. Debuting on February 27, the company sold 25 million shares at $16 each with the chance ...

Feb 27 (Reuters) - Flagship-backed Generate Biomedicines' shares fell more than 6% in their Nasdaq debut on Friday, giving the drug developer a valuation of $1.91 billion, as lingering market ...